Direkt zum Inhalt
Merck

1625009

USP

Sulfadiazin

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

4-Amino-N-2-pyrimidinylbenzolsulfonamid, N1-(Pyrimidin-2-yl)-sulfanilamid

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

200 MG

€ 420,00

€ 420,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen

Über diesen Artikel

Empirische Formel (Hill-System):
C10H10N4O2S
CAS-Nummer:
Molekulargewicht:
250.28
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
6733588

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

InChI

1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

SMILES string

Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2

InChI key

SEEPANYCNGTZFQ-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

sulfadiazine

manufacturer/tradename

USP

mp

253 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
35033Y0001480S1800000
Sulfadiazine European Pharmacopoeia (EP) Reference Standard

S1800000

Sulfadiazine

grade

pharmaceutical primary standard

grade

analytical standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

clinical testing

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

API family

sulfadiazine

API family

-

API family

sulfadiazine

API family

sulfadiazine

mp

253 °C (dec.) (lit.)

mp

253 °C (dec.) (lit.)

mp

253 °C (dec.) (lit.)

mp

253 °C (dec.) (lit.)

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sulfadiazine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Silver Sulfadiazine Cream
  • Sulfadiazine
  • Sulfadiazine Sodium
  • Sulfadiazine Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2

Lagerklasse

11 - Combustible Solids


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

U Kronawitter et al.
Deutsche medizinische Wochenschrift (1946), 118(46), 1683-1686 (1993-11-19)
A 45-year-old man with AIDS was treated for a recurrence of cerebral toxoplasmosis with sulphadiazine, 4 g, and pyrimethamine, 75 mg, daily. Owing to a lack of appetite and dysphagia he drank rather little water during the first week of
K Becker et al.
Medicine, 75(4), 185-194 (1996-07-01)
We performed a computerized search on sulfadiazine-associated nephrotoxicity reported in human immunodefiency virus (HIV)-infected patients in the international literature. Including an original case report, we summarized 35 acquired immunodefiency syndrome (AIDS) patients from 1987 to 1995 in an analysis comparing
Charlotte Catalano-Pons et al.
Pediatric nephrology (Berlin, Germany), 19(8), 928-931 (2004-06-19)
Sulfadiazine-associated urinary calculi have been described in HIV-positive adult patients but rarely in children. We report two pediatric cases of sulfadiazine-induced nephrolithiasis and review 45 adult cases from the literature. One had a hyper-IgM syndrome and was treated with sulfadiazine
D I Simon et al.
Archives of internal medicine, 150(11), 2379-2384 (1990-11-01)
Toxoplasma gondii encephalitis is an important opportunistic infection in the acquired immunodeficiency syndrome, estimated to occur in 20,000 to 40,000 patients with acquired immunodeficiency syndrome in the United States by 1991. The combination of sulfadiazine and pyrimethamine is regarded as
S Hoffmann
Scandinavian journal of plastic and reconstructive surgery, 18(1), 119-126 (1984-01-01)
Topical antibacterial treatment is of major importance in the burn patient. Silver sulfadiazine is an effective agent with low toxicity and few side effects. Deposition of silver in tissues, and absorption of sulfadiazine are both minimal. Present and future problems

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung